- >99,9%
- Detection rate
of Ninalia NIPT test
- 1
- Single blood sample
- 10
- Available from week 10
of pregnancy
- 5
- Results available
within 5 working days
- 95%
- Can minimize unnecessary invasive sampling by 95%
NIPT
Non-Invasive Prenatal Testing for trisomies 13, 18 and 21
Non-Invasive Prenatal screening Test is an innovative genetic test for pregnant women at risk of foetal Down syndrome (trisomy 21), Edwards’ syndrome (trisomy 18), and Patau syndrome (trisomy 13).
Now, this test also makes it possible to screen for other rarer chromosome abnormalities: autosomal abnormalities, deletions and duplications greater than 7 megabases.
It can be performed with a single blood sample obtained from 10 weeks (gestational age), which is equivalent to being eight weeks pregnant.
Eurofins Biomnis in figures
As a French laboratory and European leader in specialised medical pathology testing, Eurofins Biomnis has been an expert in the new generation of DNA sequencing techniques for many years and has acquired extensive know-how in the areas of prenatal genetics and biology.
Experts in their fields, the qualified prenatal diagnostics biologists responsible for Ninalia NIPT at Eurofins Biomnis support prescribers, Laboratories and their patients in the implementation of this innovative genetic test.
- 125
- years of expertise in specialised biology
- 330
- healthcare professionals
and techniciens in France
- 250000
- Ninalia NIPT tests
since october 2014
- 200000
- maternal serum markers tests performed
in 2021
- 600
- karyotypes performed
in 2016
